The oral compound that tells your body to make more growth hormone.
MK-677 mimics ghrelin to stimulate the natural, pulsatile release of your own growth hormone and IGF-1 — no injection required. Here's what the research actually shows, where the risks hide, and why we point people toward a safer, better-studied path.
Not a steroid. Not quite a SARM. Something more precise.
Ibutamoren — sold online as MK-677 — is routinely filed alongside SARMs, but pharmacologically it belongs to a different class entirely. It is a growth hormone secretagogue: a non-peptide molecule that mimics ghrelin, the body's so-called "hunger hormone," and binds the GHSR receptor in the pituitary and hypothalamus.
That single action drives the hypothalamic–pituitary–somatotropic axis — the pathway that governs GH release — to fire more of your own growth hormone in the natural, pulsatile rhythm it already uses, and over weeks raises circulating IGF-1. In older adults, it has been shown to restore GH and IGF-1 back toward youthful levels. Because it's orally active with a half-life near 24 hours, one daily dose keeps that signaling elevated without a needle, injection site, or reconstitution.
"It doesn't add growth hormone from the outside. It convinces your body to make more of its own."
It wasn't invented in a bodybuilding lab.
Ibutamoren was developed by pharmaceutical researchers chasing a specific problem: real growth hormone works, but it has to be injected, it's expensive, and dosing it directly overrides your body's own feedback loops. The prize was an orally active molecule that could coax the body into making more of its own GH — on its own schedule — for people whose production had fallen off with age, illness, or deficiency.
Through the late 1990s and 2000s, trials showed it did exactly that — restoring GH and IGF-1 in older adults toward the levels of much younger people, improving nitrogen balance, sleep, and bone turnover. It was studied for frailty, hip-fracture recovery, and muscle wasting. It was never approved and brought to market as a medicine — but those same trials are why the compound is so widely discussed today.
One receptor, a cascade downstream.
The mechanism is well characterized. What it means for you long-term is the part still being studied.
Mimics ghrelin
Binds the GHSR receptor in the pituitary and hypothalamus — the same site your natural ghrelin uses.
Amplifies GH pulses
Increases the amplitude of your body's own pulsatile growth hormone release, rather than flooding it with a flat dose.
Raises IGF-1
Sustained GH elevation drives a steady rise in IGF-1 — the hormone behind much of GH's anabolic and recovery signaling.
Works upstream
Because it acts on your own axis, it doesn't shut down endogenous production the way injected HGH can — though IGF-1 stays chronically elevated.
The reported effects — with the caveats intact.
These are effects described across clinical trials and user literature. Response varies with dose, individual, and study quality — read the qualifiers, not just the headlines.
Lean mass & nitrogen balance
Controlled trials report gains of roughly 2–3 kg in fat-free mass over eight weeks, with subjects shifting into positive nitrogen balance as early as days 2–7.
Sleep depth & recovery
An early trial recorded close to a 50% increase in REM sleep alongside deeper slow-wave sleep — one of the most consistently reported early effects, plausibly downstream of the GH/IGF-1 rise.
Bone mineral density
Oral dosing raises markers of bone turnover, and longer studies show measurable increases in bone mineral density — one of the more durable, well-documented outcomes.
Connective tissue & joints
Elevated IGF-1 is associated with collagen synthesis and tendon repair — a frequent anecdotal reason athletes cite for use.
Skin, hair & nails
Reported improvements in skin quality and hair growth track with the broader collagen and IGF-1 story rather than direct evidence.
Appetite & body weight
Ghrelin agonism reliably increases hunger. For some this aids a bulk; for others it's an unwanted, hard-to-control side effect.
What actually happens, and when.
Nothing arrives all at once. Assuming a steady daily dose, this is the sequence trials and users tend to describe — fast signals first, the meaningful structural changes much later.
Appetite & sleep
Hunger is usually the first sign the compound is active — often within a day. Many also report falling asleep faster and waking more rested inside the first week.
Fullness & water
As IGF-1 climbs, muscles look fuller and pumps improve — partly real, partly fluid. Some puffiness in the hands and face is common in this window.
Recovery & lean mass
Training recovery improves and lean mass creeps up — trials show roughly 2–3 kg of fat-free mass by week eight. This is where the "I recover faster" reports cluster.
Bone & connective tissue
The durable changes — bone mineral density, tendon and collagen remodeling — build over months, not weeks. It's also when long-term metabolic monitoring matters most.
MK-677 isn't your only route to more GH.
If the goal is more growth-hormone signaling, there are three broad paths. They differ enormously in how they work, how they're regulated, and how much medical oversight comes with them.
Injectable HGH
Synthetic growth hormone, added directly. Powerful and fast — but expensive, injected, prescription-only, and it can suppress your own production by overriding the body's feedback loops.
MK-677 (Ibutamoren)
Oral, convenient, and it works with your own axis rather than replacing GH. But it's unregulated, not FDA-approved, gray-market in purity, and it keeps IGF-1 chronically elevated with real metabolic trade-offs.
Physician-guided peptides
Prescribed GH secretagogues that also prompt your own GH release — but dispensed through licensed pharmacies, dosed by a clinician, and tracked with real bloodwork. The same underlying biology, with the oversight the gray market can't offer.
What the sales pages tend to leave out.
MK-677 is not a benign supplement. Its mechanism is real, and so is its side-effect profile. Just as important: it exists almost entirely in an unregulated market.
Not approved by the FDA for any use. Sold as a "research chemical, not for human consumption." Banned by WADA in and out of competition. Purity and dosing in the gray market vary widely between sellers.
Increased appetite
A direct result of ghrelin agonism — often the first and most noticeable effect, and difficult to override on a cut.
Water retention & edema
Fluid retention, puffiness and occasional joint discomfort are common, especially at higher doses early on.
Insulin sensitivity & blood glucose
Elevated GH/IGF-1 can raise fasting glucose and reduce insulin sensitivity — a meaningful concern for anyone with metabolic risk.
Lethargy & grogginess
Some users report daytime tiredness or a "foggy" feeling, particularly when dosing timing isn't dialed in.
Unknown long-term safety
Chronically elevated IGF-1 has open questions around long-term risk. Robust multi-year human safety data simply doesn't exist yet.